H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating on Stoke Therapeutics (STOK – Research Report) today and set a price target of $30.00. The company’s shares closed last Friday at $23.40.
According to TipRanks.com, Chattopadhyay is a 5-star analyst with an average return of 18.3% and a 51.8% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Allogene Therapeutics, and Molecular Partners AG.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Stoke Therapeutics with a $37.00 average price target, representing a 60.3% upside. In a report issued on July 9, Canaccord Genuity also reiterated a Buy rating on the stock with a $44.00 price target.
The company has a one-year high of $39.04 and a one-year low of $15.82. Currently, Stoke Therapeutics has an average volume of 133.4K.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of STOK in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. It is a biotechnology firm that focuses to increase gene expression to treat severe genetic diseases, including genetic conditions affecting the central nervous system, eye, ear, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.